vs
Side-by-side financial comparison of HeartSciences Inc. (HSCS) and Lifeward Ltd. (LFWD). Click either name above to swap in a different company.
Lifeward Ltd. is the larger business by last-quarter revenue ($200.0K vs $2.4K, roughly 82.7× HeartSciences Inc.). Lifeward Ltd. runs the higher net margin — -2674.0% vs -97179.4%, a 94505.4% gap on every dollar of revenue.
Meril Life Sciences is an Indian multinational medical device company, with headquarters in Vapi, Gujarat, India. It was founded in 2006 and is a part of the Bilakhia Group. The company is engaged in the manufacturing of vascular intervention devices, orthopedic implants, robotics, endosurgery, ENT products and in-vitro diagnostics. Meril Life Sciences operates in over 150 countries and has employed 10000 people, as of 2024.
HSCS vs LFWD — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.4K | $200.0K |
| Net Profit | $-2.4M | $-5.3M |
| Gross Margin | 58.3% | — |
| Operating Margin | -85713.2% | -2559.0% |
| Net Margin | -97179.4% | -2674.0% |
| Revenue YoY | — | 100.0% |
| Net Profit YoY | -12.9% | 65.0% |
| EPS (diluted) | $-0.85 | $-15.92 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.4K | $200.0K | ||
| Q3 25 | $1.9K | $300.0K | ||
| Q2 25 | — | $400.0K | ||
| Q1 25 | $0 | $500.0K | ||
| Q4 24 | — | $100.0K | ||
| Q3 24 | — | $612.0K | ||
| Q2 24 | — | $499.0K | ||
| Q1 24 | $14.7K | $489.0K |
| Q4 25 | $-2.4M | $-5.3M | ||
| Q3 25 | $-2.1M | $-3.2M | ||
| Q2 25 | — | $-6.6M | ||
| Q1 25 | $-2.5M | $-4.8M | ||
| Q4 24 | — | $-15.3M | ||
| Q3 24 | — | $-3.1M | ||
| Q2 24 | — | $-4.3M | ||
| Q1 24 | $-1.6M | $-6.3M |
| Q4 25 | 58.3% | — | ||
| Q3 25 | 60.0% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 69.0% | — |
| Q4 25 | -85713.2% | -2559.0% | ||
| Q3 25 | -98637.8% | -1046.7% | ||
| Q2 25 | — | -1640.8% | ||
| Q1 25 | — | -970.6% | ||
| Q4 24 | — | -15228.0% | ||
| Q3 24 | — | -518.6% | ||
| Q2 24 | — | -890.4% | ||
| Q1 24 | -10376.7% | -1329.7% |
| Q4 25 | -97179.4% | -2674.0% | ||
| Q3 25 | -108157.6% | -1056.7% | ||
| Q2 25 | — | -1640.5% | ||
| Q1 25 | — | -966.8% | ||
| Q4 24 | — | -15278.0% | ||
| Q3 24 | — | -503.9% | ||
| Q2 24 | — | -862.5% | ||
| Q1 24 | -11182.4% | -1283.4% |
| Q4 25 | $-0.85 | $-15.92 | ||
| Q3 25 | $-1.58 | $-0.20 | ||
| Q2 25 | — | $-0.58 | ||
| Q1 25 | $-2.57 | $-0.46 | ||
| Q4 24 | — | $-38.38 | ||
| Q3 24 | — | $-0.35 | ||
| Q2 24 | — | $-0.50 | ||
| Q1 24 | $-3.01 | $-0.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.0M | $2.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.2M | $8.4M |
| Total Assets | $6.0M | $22.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0M | $2.2M | ||
| Q3 25 | $2.8M | $2.0M | ||
| Q2 25 | — | $5.1M | ||
| Q1 25 | $2.6M | $5.7M | ||
| Q4 24 | — | $6.7M | ||
| Q3 24 | — | $10.7M | ||
| Q2 24 | — | $15.1M | ||
| Q1 24 | $7.1M | $20.7M |
| Q4 25 | $4.2M | $8.4M | ||
| Q3 25 | $3.1M | $12.8M | ||
| Q2 25 | — | $15.1M | ||
| Q1 25 | $1.8M | $18.5M | ||
| Q4 24 | — | $18.8M | ||
| Q3 24 | — | $33.9M | ||
| Q2 24 | — | $36.7M | ||
| Q1 24 | $8.6M | $40.6M |
| Q4 25 | $6.0M | $22.9M | ||
| Q3 25 | $6.4M | $23.2M | ||
| Q2 25 | — | $26.8M | ||
| Q1 25 | $5.7M | $28.8M | ||
| Q4 24 | — | $30.5M | ||
| Q3 24 | — | $45.8M | ||
| Q2 24 | — | $51.0M | ||
| Q1 24 | $10.8M | $55.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.3M | $-3.6M |
| Free Cash FlowOCF − Capex | — | $-3.6M |
| FCF MarginFCF / Revenue | — | -1783.0% |
| Capex IntensityCapex / Revenue | — | 5.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.3M | $-3.6M | ||
| Q3 25 | $-2.0M | $-3.8M | ||
| Q2 25 | — | $-3.9M | ||
| Q1 25 | $-1.6M | $-5.5M | ||
| Q4 24 | — | $-4.0M | ||
| Q3 24 | — | $-4.5M | ||
| Q2 24 | — | $-5.6M | ||
| Q1 24 | $-2.1M | $-7.7M |
| Q4 25 | — | $-3.6M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-5.5M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-2.1M | — |
| Q4 25 | — | -1783.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -1099.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -14352.1% | — |
| Q4 25 | — | 5.5% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | 59.8% | 0.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
